The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 08, 2025
Filed:
Nov. 03, 2021
Applicant:
Legend Biotech Usa Inc., Wilmington, DE (US);
Inventors:
Xiaohu Fan, Edmonton, CA;
Qiuchuan Zhuang, Jiangsu, CN;
Pingyan Wang, Anhui, CN;
Lin Wang, Jiangsu, CN;
Lei Yang, Anhui, CN;
Jiaying Hao, Jiangsu, CN;
Dan Zhao, Jiangsu, CN;
Xian He, Jiangsu, CN;
Assignee:
LEGEND BIOTECH USA INC., Wilmington, DE (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C07K 19/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4215 (2025.01); A61K 40/4221 (2025.01); A61K 40/4222 (2025.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); C07K 19/00 (2013.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); A61K 2239/29 (2023.05); A61K 2239/48 (2023.05); C07K 2317/22 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01);
Abstract
The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.